Switch theme
Sign up to access all valuation multiples
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
2006
274
LTM Revenue $60.5M
LTM EBITDA -$194M
$1.0B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Ocular Therapeutix has a last 12-month revenue (LTM) of $60.5M and a last 12-month EBITDA of -$194M.
In the most recent fiscal year, Ocular Therapeutix achieved revenue of $63.7M and an EBITDA of -$176M.
Ocular Therapeutix expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Ocular Therapeutix valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $60.5M | XXX | $63.7M | XXX | XXX | XXX |
| Gross Profit | $54.9M | XXX | $58.1M | XXX | XXX | XXX |
| Gross Margin | 91% | XXX | 91% | XXX | XXX | XXX |
| EBITDA | -$194M | XXX | -$176M | XXX | XXX | XXX |
| EBITDA Margin | -320% | XXX | -276% | XXX | XXX | XXX |
| EBIT | -$203M | XXX | -$172M | XXX | XXX | XXX |
| EBIT Margin | -335% | XXX | -270% | XXX | XXX | XXX |
| Net Profit | -$214M | XXX | -$194M | XXX | XXX | XXX |
| Net Margin | -353% | XXX | -304% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Ocular Therapeutix's stock price is $8.
Ocular Therapeutix has current market cap of $1.3B, and EV of $1.0B.
See Ocular Therapeutix trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.0B | $1.3B | XXX | XXX | XXX | XXX | $-1.31 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Ocular Therapeutix has market cap of $1.3B and EV of $1.0B.
Ocular Therapeutix's trades at 15.7x EV/Revenue multiple, and -5.7x EV/EBITDA.
Equity research analysts estimate Ocular Therapeutix's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Ocular Therapeutix has a P/E ratio of -6.0x.
See valuation multiples for Ocular Therapeutix and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.3B | XXX | $1.3B | XXX | XXX | XXX |
| EV (current) | $1.0B | XXX | $1.0B | XXX | XXX | XXX |
| EV/Revenue | 16.5x | XXX | 15.7x | XXX | XXX | XXX |
| EV/EBITDA | -5.2x | XXX | -5.7x | XXX | XXX | XXX |
| EV/EBIT | -4.9x | XXX | -5.8x | XXX | XXX | XXX |
| EV/Gross Profit | 18.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | -6.0x | XXX | -6.6x | XXX | XXX | XXX |
| EV/FCF | -5.2x | XXX | -7.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialOcular Therapeutix's last 12 month revenue growth is 1%
Ocular Therapeutix's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.8M for the same period.
Ocular Therapeutix's rule of 40 is -113% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Ocular Therapeutix's rule of X is -319% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Ocular Therapeutix and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 1% | XXX | 3% | XXX | XXX | XXX |
| EBITDA Margin | -320% | XXX | -276% | XXX | XXX | XXX |
| EBITDA Growth | 21% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -113% | XXX | -276% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -319% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.8M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 8% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 200% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 361% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Ocular Therapeutix acquired XXX companies to date.
Last acquisition by Ocular Therapeutix was XXXXXXXX, XXXXX XXXXX XXXXXX . Ocular Therapeutix acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Ocular Therapeutix founded? | Ocular Therapeutix was founded in 2006. |
| Where is Ocular Therapeutix headquartered? | Ocular Therapeutix is headquartered in United States of America. |
| How many employees does Ocular Therapeutix have? | As of today, Ocular Therapeutix has 274 employees. |
| Who is the CEO of Ocular Therapeutix? | Ocular Therapeutix's CEO is Dr. Pravin U. Dugel, M.D.. |
| Is Ocular Therapeutix publicy listed? | Yes, Ocular Therapeutix is a public company listed on NAS. |
| What is the stock symbol of Ocular Therapeutix? | Ocular Therapeutix trades under OCUL ticker. |
| When did Ocular Therapeutix go public? | Ocular Therapeutix went public in 2014. |
| Who are competitors of Ocular Therapeutix? | Similar companies to Ocular Therapeutix include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Ocular Therapeutix? | Ocular Therapeutix's current market cap is $1.3B |
| What is the current revenue of Ocular Therapeutix? | Ocular Therapeutix's last 12 months revenue is $60.5M. |
| What is the current revenue growth of Ocular Therapeutix? | Ocular Therapeutix revenue growth (NTM/LTM) is 1%. |
| What is the current EV/Revenue multiple of Ocular Therapeutix? | Current revenue multiple of Ocular Therapeutix is 16.5x. |
| Is Ocular Therapeutix profitable? | Yes, Ocular Therapeutix is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Ocular Therapeutix? | Ocular Therapeutix's last 12 months EBITDA is -$194M. |
| What is Ocular Therapeutix's EBITDA margin? | Ocular Therapeutix's last 12 months EBITDA margin is -320%. |
| What is the current EV/EBITDA multiple of Ocular Therapeutix? | Current EBITDA multiple of Ocular Therapeutix is -5.2x. |
| What is the current FCF of Ocular Therapeutix? | Ocular Therapeutix's last 12 months FCF is -$191M. |
| What is Ocular Therapeutix's FCF margin? | Ocular Therapeutix's last 12 months FCF margin is -317%. |
| What is the current EV/FCF multiple of Ocular Therapeutix? | Current FCF multiple of Ocular Therapeutix is -5.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
